- Titre
- Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study
- Créateurs - sans rôle
- Andrew Menzies-Gow - Royal Brompton HospitalJonathan Corren - University of California, Los AngelesArnaud Bourdin - Hôpital Arnaud de VilleneuveGeoffrey Chupp - Yale School of MedicineElliot Israel - Brigham and Women's HospitalJanet Griffiths - Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAÅsa Hellqvist - Biometrics, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, SwedenKarin Bowen - Biometrics, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USAPrimal Kaur - Amgen, Thousand Oaks, CA, USAGun Almqvist - Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, SwedenSandhia Ponnarambil - Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UKGene Colice - Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA
- Détails de publication
- Journal of allergy and clinical immunology, Vol.147(2), pp.AB249-AB249
- Éditeur
- Elsevier Inc
- Identifiants
- 99158800309311
- Unité académique
- Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
- Langue
- English
- Type de ressource
- Journal article
Article de revue
Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study
Journal of allergy and clinical immunology, Vol.147(2), pp.AB249-AB249
01/02/2021
Indicateurs
1 Consultations de la notice